Clinical trials: Hepatitis B, completed
Chronic Hepatitis B
Evaluation of cccDNA and Total HBV DNA Kinetics in Lymphocytes, Total Blood and Serum in Chronic Hepatitis B Patients Treated With Adefovir Dipivoxil and Peg Interferon Alpha 2a
Serum HBV DNA is a referent but insufficient marker of therapeutic follow-up in chronic hepatitis B treatment. Intra hepatic cccDNA disappearance reflects HBV eradication in the liver.
- Trial name
- DNA-EVAL (NCT00199732)
- Where
- 4 sites in France
- Volunteers
- 19 people
- Sponsor
- University Hospital, Limoges
Hepatitis B
Open-Label Study of the Safety and Immunogenicity of HEPLISAV™ Hepatitis B Virus Vaccine
The purpose of this study is to further evaluate the safety and seroprotective immune response of a new investigational hepatitis B virus (HBV) vaccine, HEPLISAV™, in subjects 11-55 years old.
- Trial name
- NCT00511095
- Testing
- HEPLISAV
- Where
- 7 sites in United States
- Volunteers
- 207 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
Hepatitis B
A Bridging Study: Comparing Two Lots of Sci-B-Vac™ and Engerix-B in Healthy Adults
This was a single-blind, 3-arm, comparative, controlled, randomized, study conducted at one site in Vietnam whose primary objective was to demonstrate clinical equivalence of the two production lots of Sci-B-Vac vaccine produced…
- Trial name
- NCT04531098
- Testing
- Sci-B-Vac-Lot B, Sci-B-Vac-Lot A, Engerix-B
- Where
- Vietnam
- Volunteers
- 402 people, healthy volunteers welcome
- Sponsor
- VBI Vaccines Inc.
Liver Fibrosis
Evaluation of Innovative Ultrasonic Techniques for Non-invasive Diagnosis of Liver Fibrosis in Patients With Chronic Viral Hepatitis B or C
The non-invasive assessment of liver fibrosis in chronic viral hepatitis B and C is now entering clinical practice. It is based on blood tests, especially FibroMetre® and Fibrotest® and on elastography with the Fibroscan®.
- Trial name
- FIBRECHO (NCT01537965)
- Testing
- Fibroscan® of Echosens, Aixplorer® of Supersonic Imagine, Aplio XG of Toshiba, QRS software developed by Pr I.Bricault, Acuson S2000 of Siemens
- Where
- France
- Volunteers
- 96 people
- Sponsor
- University Hospital, Grenoble
Disorder Related to Transplantation, Virus Diseases
Replacement of Lamivudine by Telbivudine to Improve Renal Function
Nephrotoxicity is one of the adverse effects of lamivudine and dosage of lamivudine has to be reduced if patients' renal function is insufficiency. Telbivudine may improve glomerular filtration rate.
- Conditions
- Disorder Related to Transplantation, Virus Diseases, Injury Due to Exposure to External Cause
- Trial name
- NCT02447705
- Testing
- telbivudine
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Chang Gung Memorial Hospital
Chronic Hepatitis B
Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B
The primary objective of this study is to evaluate the efficacy of tenofovir disoproxil fumarate (TDF) plus peginterferon α-2a (Peg-IFN) combination therapy for 48 weeks versus standard of care TDF monotherapy or Peg-IFN…
- Trial name
- NCT01277601
- Testing
- TDF, Peg-IFN
- Where
- 171 sites in United States, Australia and 17 more
- Volunteers
- 751 people
- Sponsor
- Gilead Sciences
Chronic Hepatitis B
Safety and Tolerability of TG1050: A Dose-finding Study
Methodology: This is a double-blind, randomized, placebo-controlled, multi-cohort Phase 1/1b study in patients that are currently being treated for chronic HBV infection.
- Trial name
- NCT02428400
- Testing
- TG1050
- Where
- 12 sites in Canada, France and 1 more
- Volunteers
- 48 people
- Sponsor
- Transgene
Hepatitis B Vaccine
Immunogenicity of Hepatitis B Vaccination in Methadone Maintenance Treatment Patients
This is a randomized, controlled trial. The study will evaluate the immunogenicity, immune persistence, and safety of 20 µg and 60 µg recombinant hepatitis B vaccine with three injections at months 0, 1, and 6 in methadone…
- Trial name
- NCT02991599
- Testing
- 60 µg dose hepatitis B vaccine, 20 µg dose hepatitis B vaccine
- Volunteers
- 196 people
- Sponsor
- Shanxi Medical University
Healthy
Safety and Immunogenicity Study of the Hepatitis B Vaccine, HEPLISAV™, Compared to Engerix-B® Vaccine
The purpose of the study is to evaluate the safety and immunogenicity of an investigational hepatitis B vaccine (HEPLISAV) in adults 18 to 70 years of age.
- Trial name
- NCT02117934
- Testing
- HEPLISAV, Engerix-B
- Where
- 40 sites in United States
- Volunteers
- 8,374 people, healthy volunteers welcome
- Sponsor
- Dynavax Technologies Corporation
HIV, Hepatitis C
Behavioral Science Aspects of Rapid Test Acceptance
The relevance of this research to public health is to make it possible to test for hepatitis C and syphilis at point of care so that people will receive their results immediately instead of requiring people to wait for at least a…
- Conditions
- HIV, Hepatitis C, Hepatitis B, Syphilis
- Trial name
- BSARTA (NCT01317784)
- Testing
- Rapid tests for HIV, HCV, HBV, and syphilis, HIV/HCV, HIV/syphilis
- Where
- United States
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- California State University, Long Beach
Hepatitis B, ESRD (End Stage Renal Disease)
Comparing Hepatitis B Vaccination Schedules in Patients on Hemodialysis
People with kidney failure who are on dialysis have a weaker immune response to the hepatitis B vaccine than healthy people. Even after vaccination, many dialysis patients do not develop enough protection against hepatitis B…
- Conditions
- Hepatitis B, ESRD (End Stage Renal Disease), Kidney Failure, Chronic
- Trial name
- 3v4-HEP-DOSE (NCT07784452)
- Testing
- Recombinant Hepatitis B Vaccine - 3-Dose Schedule, Recombinant Hepatitis B Vaccine - 4-Dose Schedule
- Where
- Pakistan
- Volunteers
- 104 people
- Sponsor
- Jinnah Hospital
Hib Disease, Hepatitis B
Immune Memory Foll Pry Vaccination With DTPw-HBV/Hib Vaccine Formulation; Immuno & Reacto of Booster Dose at 15-18 Mths
To assess the anti-PRP antibody response one month after vaccination in the groups receiving a fourth consecutive dose of two formulations of DTPw-HBV/Hib vaccine
- Conditions
- Hib Disease, Hepatitis B, Pertussis, Prophylaxis of Diphtheria
- Trial name
- NCT00158808
- Testing
- Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib
- Where
- Philippines
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Contraception
Safety,Effectiveness and Acceptability of Sino-implant II in DR
A study to assess the contraceptive effectiveness of Sino-implant (II).
- Trial name
- NCT01594632
- Testing
- Jadelle, Sino-implant (II)
- Where
- Dominican Republic
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- FHI 360
Hepatitis B Virus
A Double-Blind Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Participants
This study will assess the safety and tolerability of RO7049389 compared to placebo in single- and multiple-ascending doses in healthy Chinese participants.
- Trial name
- NCT03570658
- Testing
- RO7049389
- Where
- China
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Hepatitis B
Persistence of Hepatitis B Antibody Levels & Immune Response to a Hepatitis B Vaccine Challenge
The purpose of this study is to determine at 5 years of age the persistence of immunity to hepatitis B that was conferred by infant vaccination with Infanrix hexa™.
- Trial name
- NCT00411697
- Testing
- Engerix™-B Kinder
- Where
- 36 sites in Germany
- Volunteers
- 301 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic
Combination Treatment With REP 2139-Ca and Pegasys in Patients With Chronic Hepatitis B
The REP 201 protocol is a small exploratory study assessing the antiviral effects and tolerability of REP 2139-Ca when used with a full course of pegylated interferon (48 weeks) in treatment naive patients or in patients already…
- Trial name
- NCT02726789
- Testing
- REP 2139-Ca, pegylated interferon, entecavir
- Volunteers
- 5 people
- Sponsor
- Replicor Inc.
Whole Cell Pertussis, Tetanus
Safety Study of Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, and Mencevax ACWY Vaccines in Children
This study will be conducted in two stages. In the diphtheria, tetanus, pertussis (DTP) booster phase, subjects will receive a booster dose of Tritanrix-HepB/Hib-MenAC or Tritanrix-HepB/Hiberix (active control) at 15 to 18 or 24…
- Conditions
- Whole Cell Pertussis, Tetanus, Hepatitis B, Diphtheria
- Trial name
- NCT00228917
- Testing
- Tritanrix-HepB/Hib-MenAC, Tritanrix-HepB/Hiberix, Mencevax-ACWY
- Where
- 2 sites in Philippines, Thailand
- Volunteers
- 798 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis B, Chronic
Efficacy and Safety Study of Tenofovir Disoproxil Fumarate (TDF) in Chinese Chronic Hepatitis B (CHB) Subjects With Advanced Fibrosis & Compensated Cirrhosis
Chronic Hepatitis B infection (CHB) is known as the most frequently identified cause of liver disease that predisposes patients to the development of hepatocellular carcinoma (HCC).
- Trial name
- NCT02224456
- Testing
- Tenofovir disoproxil fumarate
- Where
- 19 sites in China
- Volunteers
- 197 people
- Sponsor
- GlaxoSmithKline
Chronic Hepatitis B e Antigen Positive, Chronic Hepatitis B e Antigen Negative
Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B
Background: Chronic infection with the hepatitis B virus may lead to cirrhosis, liver disease, and cancer of the liver. There is no cure for the infection, but several drugs have been approved to treat it.
- Trial name
- NCT01581554
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Hepatitis b
Combination of ETV, TQ-A3334 and TQ-B2450 for CHB (Neptune Study)
This study is a single-center, randomized, prospective, open-label Phase 2 Clinical trial to evaluate efficacy and safety of ETV and TQ-A3334 combinated with/without inhibitor of TQ-B2450 versus ETV alone in chronic hepatitis B…
- Trial name
- Neptune (NCT04202653)
- Testing
- ETV, TQ-A3334, TQ-B2450
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Tongji Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.